Search Results

You are looking at 1 - 10 of 843 items for :

  • long-term follow-up x
  • Refine by Access: All content x
Clear All
Free access

H J L M Timmers, F M Brouwers, A R M M Hermus, F C G J Sweep, A A J Verhofstad, A L M Verbeek, K Pacak, and J W M Lenders

considerable number of patients without recurrent disease ( Plouin et al . 1997 , Khorram-Manesh et al . 2005 ). The aim of this study was to investigate the long-term follow-up of patients after surgery for apparently benign PHEO. Survival was compared with

Free access

Jae Hyun Park and Jong Ho Yoon

without RAI ablation as initial therapy ( Vaisman et al. 2011 , Durante et al. 2012 ). The few recurrences that develop during long-term follow-up are readily detected by neck ultrasonography and treated without affecting survival, because salvage

Free access

Pedro Weslley Rosario, Gabriela Franco Mourão, Maurício Buzelin Nunes, Marcelo Saldanha Nunes, and Maria Regina Calsolari

definition of NIFTP ( Nikiforov et al . 2016 ). Furthermore, on account of the removal of the designation ‘cancer’ will imply, as desired, a reduction in management (treatment and follow-up), more data regarding the long-term evolution of these tumours are

Restricted access

Marta Araujo-Castro, César Mínguez Ojeda, Rogelio García Centeno, María-Carmen López-García, Cristina Lamas, Felicia Alexandra Hanzu, Mireia Mora, María del Castillo Tous, Pablo Rodríguez de Vera Gómez, Paola Parra Ramírez, Cristina Alvarez-Escola, Concepción Blanco Carrera, Rebeca Barahona San Millán, Mónica Recasens, Nuria Valdés, Paola Gracia Gimeno, Paz de Miguel Novoa, Almudena Vicente, Laura Manjón, Iñigo García Sanz, Theodora Michalopoulou, and María Calatayud

with confirmed histological diagnosis of pheochromocytoma or paraganglioma and with available clinical and biochemical data before and after surgery (in the immediate and long-term follow-up) were included. Biochemical demonstration of catecholamine

Free access

Murali Kesavan, Piyush Grover, Wei-sen Lam, Phillip G Claringbold, and J Harvey Turner

.). Results Thirty-seven consecutive GEPNET patients were treated with 177 Lu-octreotate PRRT-CAPTEM between April 2009 and March 2012. One patient was lost to long-term follow-up. At the time of analysis, the median duration of follow-up was 7 years (range

Free access

Dheeraj Karamchandani, Ramiro Arias-Amaya, Nora Donaldson, Jackie Gilbert, and Klaus-Martin Schulte

to improvements in immunosuppressive therapy and long-term care. However conversely, patients are now exposed to the long-term consequences of impaired immune function. One meta-analysis of population-based studies indicates a significant increase

Free access

Elina Ritvonen, Eliisa Löyttyniemi, Pia Jaatinen, Tapani Ebeling, Leena Moilanen, Pirjo Nuutila, Ritva Kauppinen-Mäkelin, and Camilla Schalin-Jäntti

thus provide novel information regarding the evolving causes of death in acromegaly during very long-term follow-up. Whether cancer incidence is increased in acromegaly and whether cancer deaths are increased in acromegaly is still a matter of debate

Free access

Birke Bausch, Ulrich Wellner, Dirk Bausch, Francesca Schiavi, Marta Barontini, Gabriela Sanso, Martin K Walz, Mariola Peczkowska, Georges Weryha, Patrizia Dall'Igna, Giovanni Cecchetto, Gianni Bisogno, Lars C Moeller, Detlef Bockenhauer, Attila Patocs, Karoly Rácz, Dmitry Zabolotnyi, Svetlana Yaremchuk, Iveta Dzivite-Krisane, Frederic Castinetti, David Taieb, Angelica Malinoc, Ernst von Dobschuetz, Jochen Roessler, Kurt W Schmid, Giuseppe Opocher, Charis Eng, and Hartmut P H Neumann

paraganglial tumors and most of them had SDHB ( SDHB vs others, P =0.005). HNPs were mostly hereditary and caused by SDHD mutations ( SDHD vs others, P <0.001; Table 1 ). Long-term surveillance Follow-up data were available for 5 years in 78% and for

Open access

Ha Nguyen, Komal Shah, Steven G Waguespack, Mimi I Hu, Mouhammed Amir Habra, Maria E Cabanillas, Naifa L Busaidy, Roland Bassett, Shouhao Zhou, Priyanka C Iyer, Garrett Simmons, Diana Kaya, Marie Pitteloud, Sumit K Subudhi, Adi Diab, and Ramona Dadu

established, leading to much difficulty in obtaining accurate data on incidence and prevalence as well as solidifying recommendations of treatment and long-term follow-up. In addition, most studies were small size and multi-institutional with inconsistent

Free access

Christina Wei and Elizabeth C Crowne

( ). An estimated 1 in 640–700 young adults in the United States and United Kingdom is a childhood cancer survivor ( Campbell et al